| 延长辅助内分泌治疗在激素受体阳性早期乳腺癌治疗中的价值 |
| |
| 引用本文： | 都兴隆,张国强. 延长辅助内分泌治疗在激素受体阳性早期乳腺癌治疗中的价值[J]. 现代肿瘤医学, 2018, 0(12): 1942-1945. DOI: 10.3969/j.issn.1672-4992.2018.12.036 |
| |
| 作者姓名： | 都兴隆 张国强 |
| |
| 作者单位： | 哈尔滨医科大学附属肿瘤医院乳腺整形科，黑龙江 哈尔滨 150000 |
| |
| 摘 要： | 雌激素受体（estrogen receptor,ER）阳性早期乳腺癌的复发风险一直存在。MA.17试验证明，在淋巴结阳性、雌激素受体阳性的乳腺癌患者中，常规应用5年来曲唑治疗后继续应用他莫昔芬治疗，其无病生存期（disease-free survival,DFS）和整体生存期（overall survival,OS）都得到了明显改善。MA.17R试验证明，完成5年芳香化酶抑制剂治疗的患者，继续随机应用来曲唑或安慰剂，来曲唑组的DFS明显改善。在这些研究中，延长内分泌治疗能减少远期复发的绝对益处是适度的，然而其耐受性和依从性的挑战依然存在。对于完成5年常规内分泌治疗的患者，最终是选择他莫昔芬还是来曲唑来延长治疗，主要应该考虑患者的绝经状态、淋巴结情况、耐受性和潜在的利益大小这些因素。
|
| 关 键 词： | 早期乳腺癌 延长辅助内分泌治疗 他莫昔芬 芳香化酶抑制剂 |
The value of extended adjuvant endocrine therapy in hormone receptor positive early breast cancer |
| |
| Du Xinglong,Zhang Guoqiang. The value of extended adjuvant endocrine therapy in hormone receptor positive early breast cancer[J]. Journal of Modern Oncology, 2018, 0(12): 1942-1945. DOI: 10.3969/j.issn.1672-4992.2018.12.036 |
| |
| Authors: | Du Xinglong Zhang Guoqiang |
| |
| Affiliation: | Department of Breast Surgery,Harbin Medical University Cancer Hospital,Heilongjiang Harbin 150000,China. |
| |
| Abstract: | Estrogen receptor positive early breast cancer has been associated with a recurrence risk.The MA.17 trial demonstrated improved disease-free survival(DFS) with use of letrozole for 5 years after some years of tamoxifen and an overall survival advantage for this approach in women with node-positive oestrogen receptor-positive cancer at diagnosis.The recently reported MA.17R trial randomized women who had already completed 5 years of aromatase inhibitor therapy with or without previous tamoxifen to further 5 years of letrozole or placebo.DFS was significantly improved in the extended letrozole group.The absolute benefit in terms of reduced distant recurrences in these studies is modest,and tolerability and compliance challenges remain.Extended therapy with either tamoxifen or letrozole should be considered for all and decision based on menopausal status,individual risk,tolerance and magnitude of potential benefit. |
| |
| Keywords: | early-stage breast cancer extended adjuvant endocrine therapy tamoxifen aromatase inhibitor |
|
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载免费的PDF全文 |
